Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T18:22:58.816Z.
Calculation as of: 2026-10-06T18:22:58.816Z.
Quote observation: 2026-10-06T18:19:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 970d877bc7db717cbed859036c212f4e9de57f4ce891843b12d0c27006da4837
EARNINGS YIELD
N/A
Seaport Therapeutics, Inc. Common Stock
Market Cap
$942.38M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$930.32M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$912.83M
Earnings Yield
2.29%
TTM Avg
2.73%
3Y Avg
2.26%
5Y Avg
1.85%
Market Cap
$976.29M
Earnings Yield
1.42%
TTM Avg
1.18%
3Y Avg
2.75%
5Y Avg
2.30%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seaport Therapeutics, Inc. Common Stock (SPTX) | $942.38M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $938.35M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $934.97M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $953.94M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $930.32M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $968.76M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $912.83M | 2.29% | 2.73% | 2.26% | 1.85% |
| Pacira BioSciences, Inc. (PCRX)vs › | $976.29M | 1.42% | 1.18% | 2.75% | 2.30% |
| Bioventus Inc. (BVS)vs › | $898.66M | 5.81% | 3.29% | 3.29% | 3.62% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $987.62M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
